Literature DB >> 26872011

Frequent HRAS Mutations in Malignant Ectomesenchymoma: Overlapping Genetic Abnormalities With Embryonal Rhabdomyosarcoma.

Shih-Chiang Huang1, Rita Alaggio, Yun-Shao Sung, Chun-Liang Chen, Lei Zhang, Yu-Chien Kao, Narasimhan P Agaram, Leonard H Wexler, Cristina R Antonescu.   

Abstract

Malignant ectomesenchymoma (MEM) is an exceedingly rare pediatric sarcoma with a predilection for infants and young children and is composed of dual malignant mesenchymal and neuroectodermal components. Microscopically, MEM displays areas of rhabdomyosarcoma (RMS) with intermixed neuronal/neuroblastic foci. The molecular alterations associated with MEM and its relationship with embryonal RMS (ERMS) and malignant peripheral nerve sheath tumor (MPNST) have not yet been elucidated. In this study we used whole-transcriptome sequencing in 2 MEM index cases with available frozen tissue, followed by screening of the identified genetic abnormalities in 5 additional cases. No candidate fusion genes were detected by FusionSeq analysis; however, the mutation detection algorithms revealed HRAS and PTPRD hotspot mutations in both index cases, with 1 case harboring an additional FBXW7 mutation. As these mutation profiles have been previously described in ERMS we have tested their incidence in a control group of 7 age-matched ERMS. In addition, the gene signature of MEM was compared with that of RMS, MPNST, and neuronal lineage. All 7 MEM patients were male, with a mean age of 7.5 months (range, 0.6 to 17 mo). All except 1 occurred in the pelvic/urogenital region. Most cases showed ERMS elements, with occasional spindle or undifferentiated/round cell areas. The intermixed neuroectodermal components were mostly scattered ganglion cells, ganglioneuroma, or ganglioneuroblastoma. By Sanger sequencing, 6 of 7 (86%) MEMs had HRAS mutations, with no additional case harboring PTPRD or FBXW7 mutations. The only case lacking HRAS mutation showed neuroblastic micronodules without ganglion cells. The trimethylation at lysine 27 of histone H3 (H3K27me3) expression, typically lost in MPNST, was retained in all cases. In the control ERMS group, 5 of 7 (71%) showed RAS mutations, equally distributed among NRAS, KRAS, and HRAS genes. The expression profiling of MEM showed upregulation of skeletal muscle and neuronal genes, with no significant overlap with MPNST. Our results of common HRAS mutations and composite gene signature with RMS and neuronal/neuroblastic elements suggest a closer genetic link of MEM to RMS rather than to MPNST.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26872011      PMCID: PMC4905780          DOI: 10.1097/PAS.0000000000000612

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  40 in total

1.  Extensive posttreatment ganglioneuromatous differentiation of rhabdomyosarcoma: malignant ectomesenchymoma in an infant.

Authors:  Neil J Sebire; Alan D Ramsay; Marion Malone; R Anthony Risdon
Journal:  Pediatr Dev Pathol       Date:  2002-12-10

2.  Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.

Authors:  H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

Review 3.  Malignant ectomesenchymoma in the wrist of a child: case report and review of the literature.

Authors:  Orit Oppenheimer; Edward Athanasian; Paul Meyers; Cristina R Antonescu; Richard Gorlick
Journal:  Int J Surg Pathol       Date:  2005-01       Impact factor: 1.271

Review 4.  Malignant ectomesenchymoma of the cerebrum. Case report and discussion of therapeutic options.

Authors:  Elisabeth Weiss; Clemens F Albrecht; Jochen Herms; Julianne Behnke-Mursch; Arnulf Pekrun; Knut Brockmann; Clemens F Hess
Journal:  Eur J Pediatr       Date:  2005-03-04       Impact factor: 3.183

5.  High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma.

Authors:  Erik Fredlund; Markus Ringnér; John M Maris; Sven Påhlman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

6.  KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.

Authors:  Cristina R Antonescu; Akihiko Yoshida; Tianhuo Guo; Ning-En Chang; Lei Zhang; Narasimhan P Agaram; Li-Xuan Qin; Murray F Brennan; Samuel Singer; Robert G Maki
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701

7.  Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.

Authors:  Masafumi Seki; Riki Nishimura; Kenichi Yoshida; Teppei Shimamura; Yuichi Shiraishi; Yusuke Sato; Motohiro Kato; Kenichi Chiba; Hiroko Tanaka; Noriko Hoshino; Genta Nagae; Yusuke Shiozawa; Yusuke Okuno; Hajime Hosoi; Yukichi Tanaka; Hajime Okita; Mitsuru Miyachi; Ryota Souzaki; Tomoaki Taguchi; Katsuyoshi Koh; Ryoji Hanada; Keisuke Kato; Yuko Nomura; Masaharu Akiyama; Akira Oka; Takashi Igarashi; Satoru Miyano; Hiroyuki Aburatani; Yasuhide Hayashi; Seishi Ogawa; Junko Takita
Journal:  Nat Commun       Date:  2015-07-03       Impact factor: 14.919

8.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

9.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

10.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.

Authors:  William Lee; Sewit Teckie; Thomas Wiesner; Leili Ran; Carlos N Prieto Granada; Mingyan Lin; Sinan Zhu; Zhen Cao; Yupu Liang; Andrea Sboner; William D Tap; Jonathan A Fletcher; Kety H Huberman; Li-Xuan Qin; Agnes Viale; Samuel Singer; Deyou Zheng; Michael F Berger; Yu Chen; Cristina R Antonescu; Ping Chi
Journal:  Nat Genet       Date:  2014-09-21       Impact factor: 38.330

View more
  6 in total

1.  Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland.

Authors:  Ilan Weinreb; Justin A Bishop; Simion I Chiosea; Raja R Seethala; Bayardo Perez-Ordonez; Lei Zhang; Yun-Shao Sung; Chun-Liang Chen; Adel Assaad; Bahram R Oliai; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-04       Impact factor: 6.394

2.  Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by RAS/RAF mutations.

Authors:  Narasimhan P Agaram; Shih-Chiang Huang; William D Tap; Leonard H Wexler; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2021-11-16       Impact factor: 5.006

Review 3.  Targeting RAS in pediatric cancer: is it becoming a reality?

Authors:  Angelina V Vaseva; Marielle E Yohe
Journal:  Curr Opin Pediatr       Date:  2020-02       Impact factor: 2.893

4.  Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.

Authors:  Andrea M Gross; Megan Frone; Karen W Gripp; Bruce D Gelb; Lisa Schoyer; Lisa Schill; Beth Stronach; Leslie G Biesecker; Dominic Esposito; Edjay Ralph Hernandez; Eric Legius; Mignon L Loh; Staci Martin; Deborah K Morrison; Katherine A Rauen; Pamela L Wolters; Dina Zand; Frank McCormick; Sharon A Savage; Douglas R Stewart; Brigitte C Widemann; Marielle E Yohe
Journal:  Am J Med Genet A       Date:  2020-01-08       Impact factor: 2.578

5.  Comprehensive genomic profiling of EWSR1/FUS::CREB translocation-associated tumors uncovers prognostically significant recurrent genetic alterations and methylation-transcriptional correlates.

Authors:  Josephine K Dermawan; Fabio Vanoli; Laurie Herviou; Yun-Shao Sung; Lei Zhang; Samuel Singer; William D Tap; Ryma Benayed; Tejus A Bale; Jamal K Benhamida; Brendan C Dickson; Cristina R Antonescu
Journal:  Mod Pathol       Date:  2022-03-28       Impact factor: 8.209

6.  Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma.

Authors:  Joshua T Kowalczyk; Xiaolin Wan; Edjay R Hernandez; Ruibai Luo; Gaelyn C Lyons; Kelli M Wilson; Devorah C Gallardo; Kristine A Isanogle; Christina M Robinson; Arnulfo Mendoza; Christine M Heske; Jinqui-Qiu Chen; Xiaoling Luo; Alexander E Kelly; Simone Difilippantinio; Robert W Robey; Craig J Thomas; Dan L Sackett; Deborah K Morrison; Paul A Randazzo; Lisa M Miller Jenkins; Marielle E Yohe
Journal:  Mol Cancer Ther       Date:  2020-11-06       Impact factor: 6.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.